Letters to the Editor
5 November 2024
Vol. 2 No. 3 (2024)
Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2220
Views
542
Downloads
0
HTML
Authors
Dear Editor,
Obstructive hypertrophic cardiomyopathy (oHCM) is a hereditary cardiac condition, affecting 1 in about 500 individuals, characterized by an atypical thickening of the heart muscle, specifically the interventricular septum...
Altmetrics
Downloads
Download data is not yet available.
Citations
Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail 2018;6:364-375. DOI: https://doi.org/10.1016/j.jchf.2018.02.010
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622-33. DOI: https://doi.org/10.1093/eurheartj/ehad637
Zampieri M, Argirò A, Marchi A, et al. Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy. Curr Cardiol Rep 2021;23:79. DOI: https://doi.org/10.1007/s11886-021-01508-0
Makhija M, Bansal A, Jakhar P, Sharma L, Kumar S, Gupta D. Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy. Int J Basic Clin Pharmacol 2024;13:568-72. DOI: https://doi.org/10.18203/2319-2003.ijbcp20241661
Yacoub MS, El-Nakhal T, Hasabo EA, et al. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Heart Fail Rev 2024;29:479-96. DOI: https://doi.org/10.1007/s10741-023-10375-6
Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2518-32. DOI: https://doi.org/10.1016/j.jacc.2021.09.1381
How to Cite
1.
Shabbir A, Yumn L, Khan E. Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy. Global Cardiol [Internet]. 2024 Nov. 5 [cited 2025 Aug. 13];2(3). Available from: https://www.globalcardiology.info/site/article/view/48
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Emanuele Monda, Giuseppe Limongelli, Unveiling the genetic aetiology of non-genetic dilated cardiomyopathy , Global Cardiology: Vol. 2 No. 4 (2024)
- Cecilia Salzillo, Lorenzo Giovannico, Giuseppe Fischetti, Gerardo Cazzato, Mario Magistro, Grazia Nucci, Gabriella Serio, Andrea Marzullo, Preliminary study on the immunohistochemical expression of galectin-3 in hypertrophic hearts , Global Cardiology: Vol. 2 No. 2 (2024)
- Giuseppe M.C. Rosano, Andrew J.S. Coats, Modulation of cardiac metabolism in heart failure , Global Cardiology: Vol. 2 No. 3 (2024)
- Wardah Rasool, Ahmed Kamal Siddiqi, Laibah Arshad Khan, Importance of patient-reported outcomes in cardiovascular illnesses , Global Cardiology: Vol. 3 No. 2 (2025)
- Stephan von Haehling, Wolfram Doehner, Ruben Evertz, Tania Garfias-Veitl, Monika Diek, Mahir Karakas, Ralf Birkemeyer, Gerasimos Fillippatos, Piotr Ponikowski, Michael Böhm, Tim Friede, Stefan D. Anker, Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial , Global Cardiology: Vol. 1 No. 1 (2023)
- Andrew J.S. Coats, Global Cardiology issue highlights , Global Cardiology: Vol. 2 No. 2 (2024)
- Ralph Stephan von Bardeleben, Muhammad Shahzeb Khan, Martin Geyer, Tim Friede, Javed Butler, Monika Diek, Jutta Heinrich, Marius Placzek, Roberto Ferrari, William T. Abraham, Ottavio Alfieri, Angelo Auricchio, Antoni Bayes-Genis, John G.F. Cleland, Gerasimos Filippatos, Finn Gustafsson, Wilhelm Haverkamp, Malte Kelm, Karl-Heinz Kuck, Ulf Landmesser, Aldo P. Maggioni, Marco Metra, Vlasis Ninios, Mark C. Petrie, Tienush Rassaf, Frank Ruschitzka, Ulrich Schäfer, P. Christian Schulze, Konstantinos Spargias, Alec Vahanian, Jose Luis Zamorano, Andreas Zeiher, Mahir Karakas, Friedrich Koehler, Mitja Lainscak, Alper Öner, Nikolaos Mezilis, Efstratios K. Theofilogiannakos, Ilias Ninios, Michael Chrissoheris, Panagiota Kourkoveli, Konstantinos Papadopoulos, Grzegorz Smolka, Wojciech Wojakowski, Krzysztof Reczuch, Fausto J. Pinto, Łukasz Wiewiórka, Zbigniew Kalarus, Marianna Adamo, Evelyn Santiago-Vacas, Tobias Friedrich Ruf, Michael Gross, Joern Tongers, Gerd Hasenfuß, Wolfgang Schillinger, Piotr Ponikowski, Stefan D. Anker, Baseline echocardiographic characteristics of patients enrolled in the randomized investigation of MitraClip device in heart failure (RESHAPE HF-2) trial: comparison with COAPT and Mitra-FR , Global Cardiology: Vol. 2 No. 2 (2024)
- Sven Christopher Aland, Christoph Gertler, Hannah Leonie Bräunig, Timo Schröder, Frank Edelmann, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Anja Sandek, Exercise capacity, iron deficiency and depressive symptoms in patients with asymptomatic chronic systolic heart failure , Global Cardiology: Vol. 2 No. 2 (2024)
- Giuseppe M.C. Rosano, Jerneja Farkas, Evolving targets for heart failure: the journey so far , Global Cardiology: Vol. 1 No. 1 (2023)
- Muhammad Ahmed, Fatima Muskan, Mohsin Zaheer, Manesh Kumar, Sawera Gul, Abdul Hadi Ansari, Muhammad Sameer Jamal, Muhammad Sohaib Asghar, M. Chadi Alraies, Shiny Teja Kolli, Praveen Kumar Komminni, Priya Hotwani, Vishal Reddy Bejugam, Safety and efficacy of left atrial appendage closure in cancer versus non-cancer patients: a systematic review and meta-analysis , Global Cardiology: Vol. 3 No. 2 (2025)
1-10 of 33
Next
You may also start an advanced similarity search for this article.
